

Table of Contents

SUPPLEMENTAL METHODS.....	2
Model Implementation Details and SAS Programming Code.....	2
Variable Details and Data Dictionary.....	3
Modified Poisson Regression with robust standard error.....	4
Analysis of Covariance (ANCOVA) with imputed values	5
Linear regression for censored data (tobit regression)	6
Median regression for censored data	7
MMRM with imputed values	8
MMRM for censored data (LMEC).....	9
SUPPLEMENTAL TABLES AND FIGURES.....	13
Supplemental Table 1: Summary of Analysis Timepoints, Assay Limits, and Choice of Imputed Values for Quantitative SARS-CoV-2 RNA Below Assay Lower Limit of Quantification in Recent Outpatient COVID-19 Trials	13
Supplemental Table 2: Proportion with RNA <LLoQ adjusting for Baseline RNA. Risk Ratios, 95% CIs and p-values among those with baseline viral RNA ≥LLoQ.....	15
Supplemental Figure 1: Consort Flow for Participants Included in Analysis	16
REFERENCES	17

SUPPLEMENTAL METHODS

Model Implementation Details and SAS Programming Code

Below is a snapshot of the first 12 observations used in the illustrative example, with descriptive details on the variables used in analysis. The following SAS programming code was used to implement each statistical model using SAS version 9.4.

Obs	PUBLICID	treatment	baserna	basernacat	visitday	rna	rnacat	changebase	lower	cenSor	rightchangebase
1	50070162	1	6.50	>= LL0Q	3	2.68	>= LL0Q	-3.82	-3.82	0	103.82
2	50070162	1	6.50	>= LL0Q	7	2.00	< LL0Q	-4.50	.	1	104.50
3	50070162	1	6.50	>= LL0Q	14	2.00	< LL0Q	-4.50	.	1	104.50
4	50120111	0	2.00	< LL0Q	3	2.00	< LL0Q	0.00	.	1	100.00
5	50120111	0	2.00	< LL0Q	7	2.00	< LL0Q	0.00	.	1	100.00
6	50120111	0	2.00	< LL0Q	14	2.00	< LL0Q	0.00	.	1	100.00
7	50140111	1	6.67	>= LL0Q	3
8	50140111	1	6.67	>= LL0Q	7	2.52	>= LL0Q	-4.15	-4.15	0	104.15
9	50140111	1	6.67	>= LL0Q	14	2.00	< LL0Q	-4.67	.	1	104.67
10	50140112	0	8.00	>= LL0Q	3	6.65	>= LL0Q	-1.35	-1.35	0	101.35
11	50140112	0	8.00	>= LL0Q	7	5.34	>= LL0Q	-2.66	-2.66	0	102.66
12	50140112	0	8.00	>= LL0Q	14	2.00	< LL0Q	-6.00	.	1	106.00

Variable Details and Data Dictionary

PUBLICID	Blinded participant ID variable for public dissemination
TREATMENT	Treatment Indicator variable: 1 = tixagevimab/cilgavimab (active) and 0 = placebo
BASERNA	Baseline viral RNA (log ₁₀ copies/ml)
BASERNACAT	Categorical Baseline viral RNA: '>= LLOQ' for quantifiable values and '< LLOQ' for values below the assay lower limit of quantification
VISITDAY	Post-Baseline Visit on day X, where X = 3, 7 or 14 days
RNA	Viral RNA (log ₁₀ copies/ml) on day X (defined by visitday). Results < LLoQ are imputed as 2 log ₁₀ copies/ml (which was the LLoQ)
RNACAT	Categorical viral RNA at on day X (defined by visitday): '>= LLOQ' for quantifiable values and '< LLOQ' for values below the assay lower limit of quantification
CHANGEBASE	Change in viral RNA (log ₁₀ copies/ml) from baseline to day X (defined by visitday): Post-Baseline RNA on day X – Baseline RNA
LOWER	Analysis variable used in regression models for censored data. Lower = viral RNA value when the post-baseline value is quantifiable, and lower = "." (i.e., missing) when the post-baseline value is <LLOQ
CENSOR	Indicator variable whether the post-baseline value is left-censored (i.e., <LLOQ): 1 = censored, 0 = not censored
RIGHTCHANGEBASE	Analysis variable used in quantile regression (as software is designed for right-censored data). changebase is transformed to a right-censored variable, calculated as: 100 – changebase

Modified Poisson Regression with robust standard error

The proportion <LLoQ can be compared between arms adjusting for baseline viral RNA using a binary regression approach, such as modified Poisson regression with robust standard error [1] fit with generalized estimating equations (GEE) using an independence working correlation structure. We implement this model using PROC GENMOD with a Poisson distribution and log link function. The REPEATED statement is included to indicate that the viral RNA values are repeated in the dataset within person with ID number **publicid**, and TYPE=IND to use an independence working correlation structure.

```
PROC GENMOD DATA=dataset;  
    CLASS publicid treatment visitday;  
    MODEL sensor = visitday treatment*visit baserna / DIST=POISSON LINK=LOG;  
    REPEATED SUBJECT=publicid / TYPE=IND;  
  
RUN;
```

Analysis of Covariance (ANCOVA) with imputed values

ANCOVA models can be implemented in SAS via several procedures. One such procedure is PROC GLM and can be implemented using the following code, including a where statement to restrict to those \geq LLOQ at baseline and to specify a post-baseline visit on Day X.

```
PROC GLM DATA=dataset;  
    WHERE basernacat = ">= LLOQ" and visitday = <insert>;  
    CLASS treatment;  
    MODEL changebase = treatment baserna / SOLUTION;  
RUN;
```

Linear regression for censored data (tobit regression)

Linear regression for censored data can be implemented in SAS using PROC LIFEREG, with restrictions in the where statement to subset to the population with baseline viral RNA \geq LLoQ and to a specific visit on Day X. The MODEL statement should reflect the left-censored nature of the viral RNA data, such that for each observation, the interval in the model (lower, upper) is the range of possible values the observation could take. For results \geq LLoQ, lower and upper values are identical and equal to the quantifiable viral RNA value. For results $<$ LLoQ, the lower is set to missing (i.e., ".") and the upper is set to the change in viral RNA from baseline to the LLoQ of 2 log₁₀ copies/ml (i.e., 2 – baseline).

```
PROC LIFEREG DATA=dataset;  
    WHERE basernacat = ">= LLOQ" and visitday = <insert>;  
    CLASS treatment;  
    MODEL (lower, changebase) = treatment baserna / DISTRIBUTION=NORMAL;  
RUN;
```

Median regression for censored data

Quantile regression for survival data can be implemented in SAS using PROC QUANTLIFE (note that PROC QUANTREG is not appropriate in our setting as it requires all observations to be observed, so does not allow for censored measurements). To specify median regression, the 50th quantile should be indicated in the options of the MODEL statement. The outcome in the MODEL statement is composed of two pieces: the response variable and a variable indicating which observations are “censored” (note: here censored values are flagged as **sensor=1**). Because this procedure has been designed to handle right-censored data, the response variable must be right censored in the analysis dataset. Therefore, we created an analysis variable called **rightchangebase** that is calculated as ‘100 – **changebase**’ to ensure all values are right censored. Results need to be transformed back to the original scale of measurement for dissemination purposes.

```
PROC QUANTLIFE DATA=dataset;  
    WHERE basernacat = “>= LLOQ” and visitday = <insert>;  
    CLASS treatment;  
    MODEL rightchangebase*sensor(1) = treatment baserna / QUANTILES=(0.50);  
RUN;
```

MMRM with imputed values

Mixed effects models for repeated measures can be implemented in SAS via PROC MIXED. Here, we use a REPEATED statement to indicate that we have repeated viral RNA values across study visits within SUBJECT labeled by **publicid**, and use an unstructured covariance structure (shown by TYPE=UN). The MODEL statement contains an interaction term between treatment and visit to calculate the treatment differences at each time point. Note: the WHERE statement only restricts the analysis to those \geq LLOQ at baseline as all post-baseline timepoints are included in the same model. If we wanted to restrict the post-baseline timepoints to include only Days 3 and 7 (as we did in our illustrative example) we would add an additional restriction here.

```
PROC MIXED DATA=dataset;  
    WHERE basernacat = ">= LLOQ";  
    CLASS publicid treatment visitday;  
    MODEL changebase = visitday treatment*visitday baserna / SOLUTION;  
    REPEATED visit / SUB=publicid TYPE=UN;  
RUN;
```


MMRM for censored data (LMEC)

The programming for the linear mixed effects model for censored data (LMEC) is more complex to implement as we wanted to create a repeated measures model with an unstructured covariance matrix. We opted to manually implement the likelihood function within PROC NL MIXED using the following programming code. Note: this code is specifically designed for two timepoints as it implements a bivariate normal distribution. The input dataset needs to be transposed so that for each time point (i.e., Day 3 and Day 7) there is a change in viral RNA and censor indicator for each person, and a new variable, **changes**, which is set to 2 if both Day 3 and Day 7 viral RNA are not missing, set to 1 if one viral RNA values is missing, and is set to missing if both Day 3 and Day 7 viral RNA are missing.

Obs	PUBLICID	treatment	baserna	basernacat	chg3	rna3	ensor3	chg7	rna7	ensor7	changes
1	50070162	1	6.50	>= LLOQ	-3.82	2.68	0	-4.50	2.00	1	2
2	50120111	0	2.00	< LLOQ	0.00	2.00	1	0.00	2.00	1	2
3	50140111	1	6.67	>= LLOQ	.	.	.	-4.15	2.52	0	1
4	50140112	0	8.00	>= LLOQ	-1.35	6.65	0	-2.66	5.34	0	2
25	50760132	1	5.15	>= LLOQ

```
PROC NLMIXED DATA=dataset_transpose;
```

```
WHERE basernacat = ">= LLOQ";
```

```
PARMS alpha3=3 alpha7=3 trt3=1 trt7=1 bsl3=3 bsl7=3 rho=0 sd3=1 sd7=1;
```

```
BOUNDS 1 > rho > -1, sd3 sd7 > 0;
```

```
pi = CONSTANT('pi');
```

```
mu3 = alpha3 + bsl3*baserna + trt3*treatment;
```

```
mu7 = alpha7 + bsl7*baserna + trt7*treatment;
```

```
z3 = (chg3-mu3)/sd3;
```

```
z7 = (chg7-mu7)/sd7;
```

```
rhosq=rho*rho;
```

IF ((**chg3** NE .) AND (**chg7** NE .)) THEN DO;

IF (**sensor3**=0 AND **sensor7**=0) THEN

L = -log(2*pi) - log(sd3) - log(sd7) - (0.5*log(1-rhosq)) - ((z3**2 - (2*rho*z3*z7) + z7**2) / (2*(1-rhosq)));

ELSE IF (**sensor3**=0 AND **sensor7**=1) THEN

L = -0.5*log(2*pi) - log(sd3) - (z3*z3/2) + log(PROBNORM((**chg7** - (mu7 + (rho*sd7*z3))) / (sd7*sqrt(1-rhosq))));

ELSE IF (**sensor3**=1 AND **sensor7**=0) THEN

L = -0.5*log(2*pi) - log(sd7) - (z7*z7/2) + log(PROBNORM((**chg3** - (mu3 + (rho*sd3*z7))) / (sd3*sqrt(1-rhosq))));

ELSE IF (**sensor3**=1 AND **sensor7**=1) THEN

L = PROBBNRM(z3, z7, rho);

END;

ELSE IF((**chg3** NE .) AND (**chg7** EQ .)) THEN DO;

IF (**sensor3** = 0) THEN L = -0.5*(log(2*pi)) - log(sd3) - (z3*z3/2);

ELSE IF (**sensor3** = 1) THEN L = log(PROBNORM(z3));

END;

```
ELSE IF ((chg3 EQ .) AND (chg7 NE .)) THEN DO;
```

```
    IF (sensor7 = 0)          THEN L = -0.5*(log(2*pi)) - log(sd7) - (z7*z7/2);
```

```
    ELSE IF (sensor7 = 1)    THEN L = log(PROBNORM(z7));
```

```
END;
```

```
ELSE IF ((chg3 EQ .) AND (chg7 EQ .)) THEN DO;
```

```
    L = .;
```

```
END;
```

```
MODEL changes ~ GENERAL(L);
```

```
RUN;
```

SUPPLEMENTAL TABLES AND FIGURES

Supplemental Table 1: Summary of Analysis Timepoints, Assay Limits, and Choice of Imputed Values for Quantitative SARS-CoV-2 RNA Below Assay Lower Limit of Quantification in Recent Outpatient COVID-19 Trials

Study	Analysis Timepoints (Days)	Assay Limits	Imputation Method
ACTIV-2 [2]	0 ^a , 3, 7, 14 ^b	LLoQ: 2 log ₁₀ copies/ml LOD: 1.4 log ₁₀ copies/ml	BLoQ and detectable → midpoint of LLoQ and LOD BLoQ and undetectable → midpoint of LOD and zero
REGEN-COV and REGEN-COV2 [3,4]	1 ^a , 7, 15, 29 1 ^a , 3, 5, 7	LLoQ: 2.85 log ₁₀ copies/ml	BLoQ and detectable → midpoint of LLoQ and zero BLoQ and undetectable → 0 log ₁₀ copies/ml
BLAZE-1 and BLAZE-4 [5–7]	1 ^a , 3, 5, 7, 11	Ct limit: 45	Negative → equal to the Ct limit (0 log ₁₀ copies/ml)
Molnupiravir [8]	1 ^a , 3, 5, 7, 14	LLoQ 3 log ₁₀ copies/ml	BLoQ → equal to the LLoQ
TACKLE [9]	1 ^a , 3, 6, 15, 29	LLoQ: 3.348 log ₁₀ copies/ml	BLoQ → midpoint of LLoQ and zero
COMET-ICE [10]	1 ^a , 8	LLoQ: 3.35 log ₁₀ copies/ml LOD: 3.17 log ₁₀ copies/ml	BLoQ and detectable → midpoint of LLoQ and LOD BLoQ and undetectable → midpoint of LOD and zero
Peginterferon Lambda-1a [11]	0 ^a , 7, 10, 14	Ct limit: 40 (i.e., LOD: 1.6 log ₁₀ copies/ml)	BLoD → Ct = 42 (i.e., 1 log ₁₀ copies/ml)
CONV-ERT [12]	0 ^a , 7, 28	LOD: 3 log ₁₀ copies/ml	BLoD → equal to the limit
TOGETHER [13]	0 ^a , 3, 7 or 0 ^a ,1-14	LOD: 1 log ₁₀ copies/ml	BLoD → 0 log ₁₀ copies/ml

STOIC [14]	0 ^a , 7, 14	Ct limit: 40	BLoD → equal to the Ct limit
Hydroxychloroquine [15]	1 ^a , 3, 7	LOD 3 log ₁₀ copies/ml	BLoD → equal to the LOD
EPIC-HR [16]	1 ^a , 3, 5, 10, 14	LOD: 2 log ₁₀ copies/ml	BLoD → midpoint of LOD and zero
MOVE-OUT [17]	1 ^a , 3, 5, 10, 15, 29	LLoQ: 2.70 log ₁₀ copies/ml	BLoQ → 1 copy lower than LLoQ
Remdesivir [18]	0 ^a , 2, 3, 7	LLoQ: 3.35 log ₁₀ copies/ml LOD: 3.17 log ₁₀ copies/ml	BLoQ and detectable → midpoint of LLoQ and zero BLoQ and undetectable → midpoint of LOD and zero
Ensitrelvir [19]	1 ^a , 2, 4, 6, 9, 14, 21	LLoQ: 2.08 log ₁₀ copies/ml	BLoQ → equal to the limit

^aBaseline Timepoint; ^bDays 21 and 28 dropped from later protocol versions. BLoQ = Below Limit of Quantification; LLoQ = Lower

Limit of Quantification; LOD = Limit of Detection; BLoD = Below Limit of Detection; Ct = Cycle Threshold. Studies identified through PubMed search and review of COVID treatment guidelines.


Supplemental Table 2: Proportion with RNA <LLoQ adjusting for Baseline RNA. Risk Ratios, 95% CIs and p-values among those with baseline viral RNA ≥LLoQ

Global P-value ^a	Day 3	Day 7	Day 14
G: GEE Model (Modified Poisson Regression) across all three days			
0.86	1.00 (0.47, 2.13) p=0.99	1.20 (0.81, 1.77) p=0.36	1.08 (0.87, 1.33) p=0.50
H: GEE Model (Modified Poisson Regression) across Days 3 and 7			
0.71	1.02 (0.51, 2.03) p=0.96	1.20 (0.79, 1.82) p=0.40	--

^aGlobal p-value based on Wald's test. Risk ratios obtained using Modified Poisson Regression with robust standard error, fit with generalized estimating equations and independence working correlation. This model is not restricted to those ≥LLoQ at baseline.

GEE = Generalized Estimating Equation; N/A = Not Applicable.

Supplemental Figure 1: Consort Flow for Participants Included in Analysis



NP = Nasopharyngeal; LLoQ = Lower Limit of Quantification

REFERENCES

1. Zou G. A modified poisson regression approach to prospective studies with binary data. *Am J Epidemiol.* **2004**; 159(7):702–706.
2. Chew KW, Moser C, Daar ES, et al. Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19. *Nat Commun. Nature Publishing Group;* **2022**; 13(1):4931.
3. Weinreich DM, Sivapalasingam S, Norton T, et al. REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19. *N Engl J Med. Massachusetts Medical Society;* **2021**; 385(23):e81.
4. Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. *N Engl J Med. Massachusetts Medical Society;* **2021**; 384(3):238–251.
5. Dougan M, Azizad M, Mocherla B, et al. A randomized, placebo-controlled clinical trial of bamlanivimab and etesevimab together in high-risk ambulatory patients with COVID-19 and validation of the prognostic value of persistently high viral load. *Clin Infect Dis Off Publ Infect Dis Soc Am.* **2021**; :ciab912.
6. Dougan M, Nirula A, Azizad M, et al. Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19. *N Engl J Med. Massachusetts Medical Society;* **2021**; 385(15):1382–1392.
7. Dougan M, Azizad M, Chen P, et al. Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID-19 [Internet]. *medRxiv*; 2022 [cited 2023 Feb 9]. p. 2022.03.10.22272100. Available from: <https://www.medrxiv.org/content/10.1101/2022.03.10.22272100v1>
8. Fischer WA, Eron JJ, Holman W, et al. A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus. *Sci Transl Med. American Association for the Advancement of Science;* **2021**; 14(628):eab17430.
9. Montgomery H, Hobbs FDR, Padilla F, et al. Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial. *Lancet Respir Med. Elsevier;* **2022**; 10(10):985–996.
10. Gupta A, Gonzalez-Rojas Y, Juarez E, et al. Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial. *JAMA.* **2022**; 327(13):1236–1246.
11. Jagannathan P, Andrews JR, Bonilla H, et al. Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial. *Nat Commun. Nature Publishing Group;* **2021**; 12(1):1967.

12. Alemany A, Millat-Martinez P, Corbacho-Monné M, et al. High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial. *Lancet Respir Med*. Elsevier; **2022**; 10(3):278–288.
13. Reis G, Moreira Silva EAS, Medeiros Silva DC, et al. Early Treatment with Pegylated Interferon Lambda for Covid-19. *N Engl J Med*. Massachusetts Medical Society; **2023**; 388(6):518–528.
14. Ramakrishnan S, Nicolau DV, Langford B, et al. Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. *Lancet Respir Med*. Elsevier; **2021**; 9(7):763–772.
15. Mitjà O, Corbacho-Monné M, Ubals M, et al. Hydroxychloroquine for Early Treatment of Adults with Mild Covid-19: A Randomized-Controlled Trial. *Clin Infect Dis Off Publ Infect Dis Soc Am*. **2020**; :ciaa1009.
16. Hammond J, Leister-Tebbe H, Gardner A, et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. *N Engl J Med*. Massachusetts Medical Society; **2022**; 386(15):1397–1408.
17. Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. *N Engl J Med*. Massachusetts Medical Society; **2022**; 386(6):509–520.
18. Gottlieb RL, Vaca CE, Paredes R, et al. Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients. *N Engl J Med*. Massachusetts Medical Society; **2022**; 386(4):305–315.
19. Mukae H, Yotsuyanagi H, Ohmagari N, et al. Efficacy and Safety of Ensitrelvir in Patients With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19): The Phase 2b Part of a Randomized, Placebo-Controlled, Phase 2/3 Study. *Clin Infect Dis*. **2022**; :ciac933.